Ann: Agreement Signed for Sale of Lyramid Limited, page-276

It is all personal guesses of course but I wouldn’t expect that Roquefort, or indeed any other company, would be looking to purchase 100% of Lyramid. Certainly not at this stage anyway. The reason I say this is because I don’t believe any company would be looking to undertake the development of the full range of potential drug products that is represented by the Midkine and Midkine antibodies areas of relevance.

I would see the Provelmare/Lyramid arrangement as essentially a facilitator arrangement whereby Provelmare will fund the Phase I developments. If the Phase I, and possibly some Phase II work is positive individual drug companies that specialise in a particular relevant drug area might then look to a sub-licensing arrangement relevant to their specific interest or interests. I have illustrated that earlier in a post referring to the field of Oncology.

Lyramid may well develop one or more drugs of its own but I would expect most of their ‘products’ are going to relate to sub-licensing agreements.

poorinvestor